Josh Griffin

Papers

Total Citations

H-Index

About

Dr. Josh Griffin is a urologic surgeon and researcher whose work focuses on optimizing perioperative care and recovery for patients undergoing major urologic oncology procedures, particularly radical cystectomy for bladder cancer. His most notable contribution is the landmark study "Alvimopan in an Enhanced Recovery Program Following Radical Cystectomy," which demonstrated that incorporating the peripherally acting μ-opioid receptor antagonist alvimopan into a structured enhanced recovery after surgery (ERAS) protocol significantly reduces postoperative ileus and shortens hospital length of stay. This work, cited 19 times, helped establish a new standard for multimodal recovery pathways in urologic oncology, directly improving patient outcomes by accelerating gastrointestinal recovery and decreasing opioid-related complications. Dr. Griffin’s research bridges the gap between pharmacologic innovation and clinical practice, providing evidence-based strategies to mitigate the high complication rates associated with radical cystectomy. His contributions have been instrumental in advancing enhanced recovery protocols, making major pelvic surgery safer and more tolerable for patients.